文献速递乳腺MR乳腺X线

乳腺MRI检出的导管原位癌:升级为浸润性癌的预测因素

Ductal Carcinoma In Situ (DCIS) at Breast MRI: Predictors of Upgrade to Invasive Carcinoma.
PubMed 文献 · Acad Radiol · 2019-11-04

研究回顾2007年1月至2016年12月60例患者61例MRI检出且钼靶阴性的导管原位癌,21.3%(13/61)术后升级为浸润性导管癌。MRI上病灶较大(40 mm vs 17 mm,p < 0.01)和活检伴粉刺坏死(38.5% vs 6.3%,p < 0.01)与升级相关。

要点

  • MRI检出导管原位癌的术后升级率为21.3%(13/61)。
  • 升级病例MRI病灶更大(40 mm vs 17 mm,p < 0.01)。
  • 活检伴粉刺坏死与升级相关(38.5% vs 6.3%,p < 0.01)。

核心结论

  • MRI检出导管原位癌的术后升级率为21.3%,MRI上病灶较大和活检伴粉刺坏死与升级为浸润性导管癌相关。

研究设计与样本

  • 回顾性病历审查,纳入2007年1月至2016年12月60例患者共61例MRI检出且MRI前1年内钼靶评估阴性的导管原位癌,复习影像和病理报告,采用Student t检验和卡方检验比较升级与未升级病例的特征。

关键影像表现/征象

  • 导致导管原位癌诊断的MRI表现:非肿块强化78.7%(48/61),强化肿块16.4%(10/61),非肿块强化伴强化肿块3.3%(2/61),强化焦点1.6%(1/61)。
  • 升级病例MRI上病灶更大(40 mm vs 17 mm,p < 0.01)。

诊断标准与关键数值

  • MRI检出导管原位癌术后升级为浸润性导管癌的比例为21.3%(13/61)。
  • 活检伴粉刺坏死在升级组为38.5%(5/13),未升级组为6.3%(3/48),p < 0.01。

临床应用与阅片要点

  • MRI检出导管原位癌时,病灶较大(如40 mm)和活检伴粉刺坏死提示术后升级为浸润性癌的风险较高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: To determine the upgrade rate of magnetic resonance imaging (MRI)-detected ductal carcinoma in situ (DCIS) and to identify patient, imaging, and pathologic features that may predict the risk of upgrade.

MATERIALS AND METHODS: Medical chart review from January 2007 to December 2016 identified 60 patients with 61 cases of MRI-detected DCIS and negative mammographic evaluations within 1 year prior to the MRI. Imaging and pathology reports were reviewed. Standard statistical tests, including Student's t-tests and chi-square tests, were used to compare patient, imaging, and pathologic features between the cases of DCIS that did and did not upgrade to invasive carcinoma at surgery.

RESULTS: Over a 10-year period, 60 patients (mean age 52 years, range 30-76 years) were diagnosed with 61 cases of MRI-detected DCIS. Two-thirds of DCIS cases were detected on MRI examinations that were performed for purposes of high-risk screening (67.2%, 41/61). MRI features that led to the DCIS diagnosis were nonmass enhancement in 78.7% (48/61), enhancing mass in 16.4% (10/61), nonmass enhancement and enhancing mass in 3.3% (2/61), and enhancing focus in 1.6% (1/61). Thirteen cases (21.3%, 13/61) were upgraded to invasive ductal carcinoma at surgery. DCIS cases that upgraded were larger on MRI (40 mm vs 17 mm, p < 0.01) and more likely to be associated with comedonecrosis at biopsy (38.5% [5/13] vs 6.3% [3/48], p < 0.01).

CONCLUSION: The upgrade rate of MRI-detected DCIS to invasive ductal carcinoma at surgery is 21.3%. Features that are associated with upgrade include large size on MRI and the presence of comedonecrosis at biopsy.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Lamb LR, Lehman CD, Oseni TO, et al. Ductal Carcinoma In Situ (DCIS) at Breast MRI: Predictors of Upgrade to Invasive Carcinoma. Acad Radiol. 2019. PMID: 31699638. doi:10.1016/j.acra.2019.09.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。